DK2318028T3 - Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer - Google Patents
Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer Download PDFInfo
- Publication number
- DK2318028T3 DK2318028T3 DK09770571.9T DK09770571T DK2318028T3 DK 2318028 T3 DK2318028 T3 DK 2318028T3 DK 09770571 T DK09770571 T DK 09770571T DK 2318028 T3 DK2318028 T3 DK 2318028T3
- Authority
- DK
- Denmark
- Prior art keywords
- activia
- activin
- solvable
- antagonists
- applications
- Prior art date
Links
- 102000005606 Activins Human genes 0.000 title 1
- 108010059616 Activins Proteins 0.000 title 1
- 239000000488 activin Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 210000003743 erythrocyte Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13336808P | 2008-06-26 | 2008-06-26 | |
| PCT/US2009/003838 WO2009158033A2 (en) | 2008-06-26 | 2009-06-26 | Antagonists of activin-actriia and uses for increasing red blood cell levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2318028T3 true DK2318028T3 (da) | 2020-05-04 |
Family
ID=41445146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09770571.9T DK2318028T3 (da) | 2008-06-26 | 2009-06-26 | Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer |
Country Status (10)
| Country | Link |
|---|---|
| EP (4) | EP2318028B1 (da) |
| JP (8) | JP5773868B2 (da) |
| KR (4) | KR20210047374A (da) |
| CN (2) | CN107252486B (da) |
| AU (4) | AU2009262968A1 (da) |
| CA (3) | CA2729054C (da) |
| DK (1) | DK2318028T3 (da) |
| ES (2) | ES2791699T3 (da) |
| NZ (2) | NZ590326A (da) |
| WO (2) | WO2009158015A2 (da) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2574777C (en) | 2004-07-23 | 2015-09-01 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EP1973559B1 (en) | 2005-11-23 | 2013-01-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| RU2473362C2 (ru) | 2007-02-01 | 2013-01-27 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
| TW202021980A (zh) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| KR20180083967A (ko) | 2007-02-09 | 2018-07-23 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| CN107412734A (zh) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| ES2949049T3 (es) * | 2008-08-14 | 2023-09-25 | Acceleron Pharma Inc | Trampas de GDF |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| WO2010083034A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| KR20210034684A (ko) | 2009-06-12 | 2021-03-30 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| AU2015203400A1 (en) * | 2009-08-13 | 2015-07-16 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
| KR102606494B1 (ko) * | 2009-08-13 | 2023-11-24 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| AU2010322011B2 (en) | 2009-11-17 | 2016-03-31 | Acceleron Pharma Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| CN103298832A (zh) * | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| GR1007832B (el) * | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| US9809636B2 (en) * | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| HK1214504A1 (zh) * | 2012-10-24 | 2016-07-29 | 细胞基因公司 | 用於治療貧血的方法 |
| RU2678117C2 (ru) * | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| JP6475639B2 (ja) * | 2013-01-25 | 2019-02-27 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン |
| WO2015161220A1 (en) * | 2014-04-18 | 2015-10-22 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating sickle-cell disease |
| CN106795224B (zh) * | 2014-06-04 | 2021-05-18 | 阿塞勒隆制药公司 | 用促滤泡素抑制素多肽治疗病症的方法和组合物 |
| BR112016029226A2 (pt) | 2014-06-13 | 2017-10-17 | Acceleron Pharma Inc | métodos e composições para o tratamento de úlceras |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| TWI773117B (zh) | 2014-12-03 | 2022-08-01 | 美商西建公司 | 活化素-actrii拮抗劑及治療貧血之用途 |
| RS61728B1 (sr) | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Jednograni fuzioni receptorski proteini tipa i i tipa ii i njihove upotrebe |
| LT3286206T (lt) | 2015-04-22 | 2021-06-10 | Biogen Ma Inc. | Naujieji hibridiniai actriib ligandų trap baltymai, skirti gydant su raumenų nykimu susijusias ligas |
| JP7072507B2 (ja) | 2015-11-23 | 2022-05-20 | アクセルロン ファーマ インコーポレイテッド | 眼の障害を処置するための方法 |
| WO2017177013A1 (en) * | 2016-04-06 | 2017-10-12 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| BR112019001615A2 (pt) | 2016-07-27 | 2019-04-30 | Acceleron Pharma Inc. | métodos e composições para tratar mielofibrose |
| CA3039525A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Variant actriib proteins and uses thereof |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| JP7139326B2 (ja) | 2016-11-10 | 2022-09-20 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 |
| KR20250059538A (ko) | 2017-11-09 | 2025-05-02 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CN112292144B (zh) | 2018-01-12 | 2025-03-21 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
| CA3098679A1 (en) * | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN113015743B (zh) * | 2018-11-15 | 2025-06-24 | 三菱化学株式会社 | 改变型激活素a |
| CA3148870A1 (en) * | 2019-08-22 | 2021-02-25 | The Regents Of The University Of California | Ube3a for the treatment of angelman syndrome |
| KR20230004515A (ko) | 2020-03-20 | 2023-01-06 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법 |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| KR20240099146A (ko) * | 2021-09-03 | 2024-06-28 | 레크나 테라퓨틱스 상하이 씨오., 엘티디. | 항-acvr2a 항체 및 이의 용도 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| EP0548276A4 (en) * | 1990-09-13 | 1993-12-29 | Children's Hospital Medical Center Of Northern California | Method for increasing red blood cell production by treatment with activin or activin-related peptides |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| JPH11502717A (ja) | 1995-04-11 | 1999-03-09 | ザ ジェネラル ホスピタル コーポレーション | 逆ツーハイブリッドシステム |
| US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| US6372454B2 (en) | 1997-08-29 | 2002-04-16 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding Follistatin-3 |
| US6953662B2 (en) * | 1997-08-29 | 2005-10-11 | Human Genome Sciences, Inc. | Follistatin-3 |
| US6468543B1 (en) * | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| CA2444854A1 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| CA2448253A1 (en) * | 2001-05-25 | 2002-11-28 | Genset S.A. | Human cdnas and proteins and uses thereof |
| US6855344B2 (en) * | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US20070184052A1 (en) * | 2003-05-09 | 2007-08-09 | Lin Herbert Y | Soluble tgf-b type III receptor fusion proteins |
| WO2005025601A1 (en) | 2003-09-15 | 2005-03-24 | Monash University | Follistatin isoforms and uses thereof |
| JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| CA2574777C (en) | 2004-07-23 | 2015-09-01 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| CA2575563A1 (en) * | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| JP2008520207A (ja) | 2004-11-16 | 2008-06-19 | アヴィディア リサーチ インスティテュート | タンパク質骨格およびその使用 |
| EP1973559B1 (en) | 2005-11-23 | 2013-01-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth |
| EA200802213A1 (ru) * | 2006-05-09 | 2009-10-30 | Химекуэст Фармасьютикалз, Инк. | Способы лечения заболеваний крови |
| CN101489704B (zh) * | 2006-07-13 | 2011-04-20 | 巴斯夫欧洲公司 | 用于制备金属成型体的含粘合剂的热塑性组合物 |
| BRPI0714882A2 (pt) * | 2006-07-21 | 2013-05-21 | Lyne Lab | composiÇço lÍquida de acetato de cÁlcio e uso de uma soluÇço aquosa que compreende entre cerca de 7% (p/v) e cerca de 21% (p/v) de acetato de cÁlcio |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| US7547781B2 (en) * | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| MY188973A (en) * | 2006-12-18 | 2022-01-17 | Acceleron Pharma Inc | Activin-actrii antagonists and uses for treating anemia |
| TW202021980A (zh) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| KR20180083967A (ko) | 2007-02-09 | 2018-07-23 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| CN107412734A (zh) * | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| DE102008016742B4 (de) * | 2008-03-31 | 2010-01-14 | Thyssenkrupp Presta Ag | Lenksäule für ein Kraftfahrzeug |
-
2009
- 2009-06-26 DK DK09770571.9T patent/DK2318028T3/da active
- 2009-06-26 KR KR1020217011646A patent/KR20210047374A/ko not_active Ceased
- 2009-06-26 CN CN201710403739.0A patent/CN107252486B/zh active Active
- 2009-06-26 EP EP09770571.9A patent/EP2318028B1/en active Active
- 2009-06-26 CA CA2729054A patent/CA2729054C/en active Active
- 2009-06-26 WO PCT/US2009/003808 patent/WO2009158015A2/en not_active Ceased
- 2009-06-26 KR KR1020197012336A patent/KR20190049912A/ko not_active Ceased
- 2009-06-26 WO PCT/US2009/003838 patent/WO2009158033A2/en not_active Ceased
- 2009-06-26 KR KR1020177008278A patent/KR102024444B1/ko active Active
- 2009-06-26 CA CA3049354A patent/CA3049354A1/en not_active Abandoned
- 2009-06-26 CA CA2729098A patent/CA2729098C/en active Active
- 2009-06-26 KR KR1020117001139A patent/KR20110031951A/ko not_active Withdrawn
- 2009-06-26 EP EP20195139.9A patent/EP3804746A1/en not_active Withdrawn
- 2009-06-26 EP EP19191414.2A patent/EP3620795A1/en not_active Withdrawn
- 2009-06-26 ES ES09770571T patent/ES2791699T3/es active Active
- 2009-06-26 EP EP09770553.7A patent/EP2303917B1/en active Active
- 2009-06-26 CN CN200980133280.0A patent/CN102131515B/zh active Active
- 2009-06-26 NZ NZ590326A patent/NZ590326A/xx unknown
- 2009-06-26 AU AU2009262968A patent/AU2009262968A1/en not_active Abandoned
- 2009-06-26 ES ES09770553T patent/ES2852699T3/es active Active
- 2009-06-26 JP JP2011516323A patent/JP5773868B2/ja active Active
- 2009-06-26 NZ NZ602471A patent/NZ602471A/en unknown
-
2014
- 2014-02-07 JP JP2014022289A patent/JP2014088438A/ja not_active Withdrawn
-
2015
- 2015-07-23 JP JP2015145499A patent/JP2015187180A/ja not_active Withdrawn
-
2016
- 2016-05-12 AU AU2016203098A patent/AU2016203098B2/en active Active
- 2016-11-11 JP JP2016220297A patent/JP2017036331A/ja not_active Withdrawn
-
2018
- 2018-06-08 AU AU2018204105A patent/AU2018204105A1/en not_active Abandoned
- 2018-09-03 JP JP2018164195A patent/JP6643432B2/ja active Active
- 2018-09-03 JP JP2018164196A patent/JP2018184484A/ja not_active Withdrawn
-
2019
- 2019-12-23 JP JP2019231523A patent/JP2020041002A/ja not_active Withdrawn
-
2020
- 2020-08-17 AU AU2020220046A patent/AU2020220046A1/en not_active Abandoned
-
2021
- 2021-10-28 JP JP2021176418A patent/JP2022023184A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2318028T3 (da) | Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer | |
| IL287990A (en) | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels | |
| DK2598483T3 (da) | Ampk-aktiverende heterocykliske forbindelser og fremgangsmåder til anvendelse af disse | |
| DK2205731T3 (da) | Anvendelse og fremstilling af citrat-stabile, neutrale metalloproteaser | |
| ME03766B (me) | Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe | |
| EP2456787A4 (en) | CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE | |
| DK2646444T3 (da) | Substituerede purin- og 7-deazapurinforbindelser som modulatorer af epigenetiske enzymer | |
| DK3321355T3 (da) | Fremgangsmåder og sammensætninger til klinisk afledning af en allogen celle og terapeutiske anvendelser | |
| DK3213738T3 (da) | Sammensætninger og fremgangsmåder til målrettet termomodulering | |
| DK2557517T3 (da) | Bestemmelse af ubalance i nukleinsyresekvens | |
| DK2459743T3 (da) | Sæt af oligonukleotidprober såvel som fremgangsmåder og anvendelser relateret dertil | |
| DK2254598T3 (da) | Kombination af alfa 7-nikotinagonister og antipsykotika | |
| DK2638149T3 (da) | Immortalisering af epitelceller og fremgangsmåder til anvendelse | |
| DK2663864T3 (da) | Fremgangsmåde til at vurdere immundiversitet og anvendelse af denne | |
| DK2531181T3 (da) | Formuleringer af rasagilin med forlænget afgivelse og anvendelser deraf | |
| DK2513193T3 (da) | Forbedrede blends af polyarylenethere og polyarylensulfider | |
| DK2647068T3 (da) | Batterielektrode og metode til fremstilling af samme | |
| DK3011975T3 (da) | Faststofsammensætning til oral administration af farvestoffer og diagnostisk anvendelse deraf | |
| EP2306823A4 (en) | 5-FLUOROCYTOSINE FORMULATIONS AND USES THEREOF | |
| FR2940608B1 (fr) | Utilisation de monosaccharides et composition | |
| DK2358714T3 (da) | Alkylcyclohexylethere af dihydrotetraazabenzoazulener | |
| EP2461806A4 (en) | SMALL ANTIANGIOGENIC MOLECULES AND METHOD OF USE THEREOF | |
| DK2268646T3 (da) | Thiazolopyridin-2-yloxy-phenyl og thiazolopyrazin-2-yloxy-phenyl-aminer som modulatorer af leukotrien-a4-hydrolase | |
| DK2525782T3 (da) | Formuleringer af nanobærere og fremgangsmåder til fremstilling deraf | |
| DK2561034T3 (da) | Anvendelse af csh-suspensioner i borehulscementering |